D role functioning (perfect score = 100) favoured the CXT arm (median change HAART = 0, CXT = +17; p=0.011). Improvement in pain (perfect score = 0, median change HAART = -16.7, CXT = -33.3; p=0.1) and overall QOL (median change HAART = 12.5, CXT = 16.7; p=0.08) were also greater in the CXT arm. Comparisons between arms were not statistically significant.NIH-PA Author Manuscript NIH-PA Author Manu
Port, we show that soluble mimics of CD4 inhibit HIV-1 infection by prematurely triggering the viral envelope glycoproteins. The unstable activated state of the virus lasts only a few minutes, after which the virus loses the ability to infect cells. This novel strategy for inhibition may be generally applicable to other viruses besides HIV-1, some of which are also activated by binding to their re
Amic changes in conformation and function of the HIV-1 envelope glycoproteins, immediately after engagement of the activating molecules. Using these tools, we found that SCMs inactivate envelope glycoprotein function by an activation-triggered inhibition process, through induction of a metastable activated state.Materials and Methods Reagents and AntibodiesFour-domain sCD4 (molecular weight 50 kDa
Infection in vitro, this protein was tested for clinical efficacy in HIV-1-infected individuals; however, no effect on plasma viral loads was observed [13]. Further examination revealed that doses of sCD4 that were significantly higher than those achieved in the clinical trial were required to neutralize primary clinical isolates of HIV-1, in contrast to the relatively sensitive, laboratory-adapte
Coproteins [1]. Binding of gp120 to the receptor, CD4, on the target cell surface induces major conformational changes in the envelope glycoproteins [2]. These changes allow gp120 to bind the viral coreceptor, either CXCR4 or CCR5 [3?]. CD4 binding also induces the formation of a gp41 pre-hairpin intermediate, in which three hydrophobic grooves on the surface of a coiled coil formed by the heptad
Ion, was used as a negative control. The YU2(Dct) protein has a truncated cytoplasmic tail of 17 amino acids, with a stop codon introduced after Ala 710 (numbered according to current convention [46]). The YU2-GS8 construct is a cleavage-defective form of the YU2 HIV-1 envelope glycoproteins that contains an 8-amino acid glycine-serine linker at the gp120/gp41 junction. Starting with the cytoplasm
Ion, was used as a negative control. The YU2(Dct) protein has a truncated cytoplasmic tail of 17 amino acids, with a stop codon introduced after Ala 710 (numbered according to current convention [46]). The YU2-GS8 construct is a cleavage-defective form of the YU2 HIV-1 envelope glycoproteins that contains an 8-amino acid glycine-serine linker at the gp120/gp41 junction. Starting with the cytoplasm
Amic changes in conformation and function of the HIV-1 envelope glycoproteins, immediately after engagement of the activating molecules. Using these tools, we found that SCMs inactivate envelope glycoprotein function by an activation-triggered inhibition process, through induction of a metastable activated state.Materials and Methods Reagents and AntibodiesFour-domain sCD4 (molecular weight 50 kDa